The company is anchoring its market entry on RTN-001, a drug designed to lower hypertension by potentiating nitric oxide signaling. This lead candidate remains the primary focus for future capital, as the firm currently navigates a phase 2b clinical trial. Management expects to release preliminary data from this study within the first half of next year.

Financial disclosures reveal a widening deficit, with net losses climbing to $7.5 million for the first half of this year, compared to $1.9 million during the same period in 2023. While the firm has yet to disclose the specific volume or pricing of the shares it plans to list, it confirmed that the proceeds are earmarked to sustain the ongoing development and testing of the RTN-001 pipeline.